| scholarly article | Q13442814 |
| P2093 | author name string | Peter Buchwald | |
| Damir Bojadzic | |||
| P2860 | cites work | Structure-Function analysis of the CTLA-4 interaction with PP2A | Q21263143 |
| BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth | Q22009942 | ||
| An integrated encyclopedia of DNA elements in the human genome | Q22122150 | ||
| Finishing the euchromatic sequence of the human genome | Q22122488 | ||
| Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses | Q24291066 | ||
| T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif | Q24310233 | ||
| CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells | Q24310570 | ||
| Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor | Q24319938 | ||
| 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB | Q24533857 | ||
| Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target | Q24559442 | ||
| Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34 | Q24568305 | ||
| Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 | Q24634871 | ||
| Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1 | Q24655393 | ||
| Estimating the size of the human interactome | Q24655438 | ||
| Distinguishing protein-coding and noncoding genes in the human genome | Q24670087 | ||
| Anti-TNF-alpha therapies: the next generation | Q34227176 | ||
| Diagnosing the decline in pharmaceutical R&D efficiency | Q34257771 | ||
| Small-molecule inhibitors of protein-protein interactions: progressing toward the reality | Q34263719 | ||
| A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. | Q34283011 | ||
| CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. | Q34300766 | ||
| Exploratory computational assessment of possible binding modes for small molecule inhibitors of the CD40-CD154 co-stimulatory interaction | Q34327307 | ||
| SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation | Q34331884 | ||
| PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta | Q34347206 | ||
| CD40 pathway blockade as an approach to immunotherapy | Q34367802 | ||
| Signaling by CD40 and its mimics in B cell activation | Q34397107 | ||
| Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials | Q34405616 | ||
| Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions | Q34481459 | ||
| Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human | Q34503355 | ||
| Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis | Q34504787 | ||
| Small-molecule modulators of 14-3-3 protein-protein interactions | Q34522489 | ||
| The CD28 signaling pathway regulates glucose metabolism | Q34525357 | ||
| CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. | Q34535434 | ||
| Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment | Q34574516 | ||
| OX40L blockade and allergen-induced airway responses in subjects with mild asthma | Q34620982 | ||
| The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members | Q34727955 | ||
| Protein therapeutics: a summary and pharmacological classification | Q34728463 | ||
| Interaction of human PD-L1 and B7-1. | Q34789854 | ||
| Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. | Q34809019 | ||
| Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction | Q34954124 | ||
| A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins | Q34960765 | ||
| The significance of OX40 and OX40L to T-cell biology and immune disease. | Q34979946 | ||
| B-1a lymphocytes attenuate insulin resistance | Q35004327 | ||
| Reconstruction of the experimentally supported human protein interactome: what can we learn? | Q35006921 | ||
| Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. | Q35087851 | ||
| The signaling adaptors and pathways activated by TNF superfamily | Q35145613 | ||
| The CD40-CD154 interaction in B cell-T cell liaisons | Q35145640 | ||
| Negative T cell costimulation and islet tolerance. | Q35146722 | ||
| Modulation of protein-protein interactions with small organic molecules | Q35151091 | ||
| Focused chemical libraries--design and enrichment: an example of protein-protein interaction chemical space | Q35158672 | ||
| The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice | Q24670319 | ||
| The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face | Q24673940 | ||
| A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints | Q26738729 | ||
| A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues | Q26776389 | ||
| Profile of atacicept and its potential in the treatment of systemic lupus erythematosus | Q26849719 | ||
| CD28 co-stimulation in T-cell homeostasis: a recent perspective | Q27007031 | ||
| Non-Canonical NF-κB Signaling Initiated by BAFF Influences B Cell Biology at Multiple Junctures | Q27024640 | ||
| Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells | Q27340853 | ||
| The structural basis for the recognition of diverse receptor sequences by TRAF2 | Q27619945 | ||
| Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes | Q27637597 | ||
| Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands | Q27637902 | ||
| BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2 | Q27639845 | ||
| Crystal structure of the BAFF–BAFF-R complex and its implications for receptor activation | Q27641056 | ||
| Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions | Q27661215 | ||
| Crystallographic and Mutational Analysis of the CD40-CD154 Complex and Its Implications for Receptor Activation | Q27666816 | ||
| Small Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture Mechanism | Q27667288 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development | Q27685122 | ||
| Protein-Protein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery | Q27704937 | ||
| 2 A crystal structure of an extracellular fragment of human CD40 ligand | Q27732546 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q27861111 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 | ||
| APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity | Q28145384 | ||
| OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells | Q28188488 | ||
| The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 | ||
| PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells | Q28242808 | ||
| BAFF, APRIL and their receptors: structure, function and signaling | Q28258238 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| The role of the BAFF/APRIL system on T cell function | Q28259870 | ||
| Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation | Q28263653 | ||
| CD40/CD40L signaling and its implication in health and disease | Q28264418 | ||
| Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay | Q28266287 | ||
| How many drug targets are there? | Q28276660 | ||
| Discovery of selective small-molecule CD80 inhibitors. | Q51798202 | ||
| Identification of small-molecule inhibitors of the JIP-JNK interaction. | Q51799265 | ||
| Aptamers as therapeutics. | Q51813594 | ||
| Regulated expression of BAFF-binding receptors during human B cell differentiation. | Q51969607 | ||
| Residue frequencies and pairing preferences at protein-protein interfaces. | Q52066467 | ||
| Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. | Q52596153 | ||
| Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. | Q52609801 | ||
| Small Molecules Drive Big Improvements in Immuno-Oncology Therapies. | Q53047113 | ||
| A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. | Q53351927 | ||
| Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. | Q53472511 | ||
| Fragment-based drug design: how big is too big? | Q53584157 | ||
| Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis | Q56901733 | ||
| Small molecule ligands define a binding site on the immune regulatory protein B7.1 | Q56904575 | ||
| An inhibitor of CD28-CD80 interactions impairs CD28-mediated costimulation of human CD4 T cells | Q56907289 | ||
| Development of a CD28 receptor binding-based screen and identification of a biologically active inhibitor | Q56907880 | ||
| CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism | Q63354517 | ||
| A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation | Q71889606 | ||
| A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis | Q73114791 | ||
| Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis | Q73166180 | ||
| Properties of known drugs. 2. Side chains | Q73284123 | ||
| Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 | ||
| Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation | Q73584853 | ||
| Drugs, leads, and drug-likeness: an analysis of some recently launched drugs | Q74210182 | ||
| Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein | Q77787608 | ||
| Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates | Q80903034 | ||
| Drug discovery. Magnificent obsession | Q81538257 | ||
| Development of small molecules designed to modulate protein-protein interactions | Q83172122 | ||
| Protein-protein interaction inhibitors get into the groove | Q83541186 | ||
| Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia | Q83757871 | ||
| Evaluation of serum soluble OX40 ligand as a prognostic indicator in acute coronary syndrome patients | Q84525766 | ||
| The TNF superfamily in 2009: new pathways, new indications, and new drugs | Q84740528 | ||
| B-cell-activating factor deficiency attenuates high-fat diet-induced glucose intolerance by potentiating adipose tissue function | Q85648513 | ||
| BAFF regulates activation of self-reactive T cells through B-cell dependent mechanisms and mediates protection in NOD mice | Q87115803 | ||
| Pioneering apoptosis-targeted cancer drug poised for FDA approval | Q95557262 | ||
| Toxicological significance of azo dye metabolism by human intestinal microbiota | Q37971640 | ||
| Targeted drug delivery for cancer therapy: the other side of antibodies | Q38058816 | ||
| Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study | Q38064894 | ||
| Challenges and approaches for the development of safer immunomodulatory biologics | Q38093772 | ||
| The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity | Q38107660 | ||
| Modulators of protein-protein interactions | Q38204807 | ||
| Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade | Q38237428 | ||
| Aptamers as targeted therapeutics: current potential and challenges | Q38290290 | ||
| Novel therapeutic targets in primary biliary cirrhosis | Q38342107 | ||
| Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance | Q38445344 | ||
| Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study | Q38453674 | ||
| KR33426, [2-(2,5-dichlorophenyl)-5-methyloxazol-4yl]carbonylguanidine, is a novel compound to be effective on mouse systemic lupus erythematosus. | Q38471626 | ||
| An increase in B cell apoptosis by interfering BAFF-BAFF-R interaction with small synthetic molecules | Q38473826 | ||
| OX40, OX40L and Autoimmunity: a Comprehensive Review. | Q38555213 | ||
| From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway | Q38560148 | ||
| Small-molecule antagonists of the immune checkpoint pathways: concept to clinic | Q38647669 | ||
| Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity | Q38681685 | ||
| Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases | Q38748557 | ||
| The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | Q38775177 | ||
| Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway | Q38824724 | ||
| 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia | Q38847477 | ||
| Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors | Q38890700 | ||
| CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function | Q38993337 | ||
| Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies | Q39010566 | ||
| A comprehensive map of molecular drug targets. | Q39026969 | ||
| Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions | Q39185042 | ||
| Aptamers for CD Antigens: From Cell Profiling to Activity Modulation | Q39191316 | ||
| Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. | Q39215637 | ||
| Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. | Q39297939 | ||
| Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative | Q39679493 | ||
| Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. | Q39730888 | ||
| Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys | Q39802327 | ||
| TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts | Q40066472 | ||
| Role of lymphokine and antigen in the control of specific T cell responses | Q40293123 | ||
| The druggable genome: an update | Q40362716 | ||
| Anti-PD-L1 peptide improves survival in sepsis | Q40404109 | ||
| Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. | Q40456758 | ||
| Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. | Q40461021 | ||
| An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. | Q40472871 | ||
| High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy. | Q40478773 | ||
| Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction | Q35523846 | ||
| TNF superfamily protein-protein interactions: feasibility of small- molecule modulation | Q35534271 | ||
| The uncertain glory of APRIL. | Q35540065 | ||
| Discovery of small molecule CD40-TRAF6 inhibitors | Q35549406 | ||
| A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction | Q35559411 | ||
| Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion | Q35563311 | ||
| Pocketome: an encyclopedia of small-molecule binding sites in 4D | Q35631012 | ||
| Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. | Q35631111 | ||
| The discovery and development of belimumab: the anti-BLyS-lupus connection | Q35691272 | ||
| CD40/CD154 interactions at the interface of tolerance and immunity | Q35698455 | ||
| Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice | Q35795164 | ||
| Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? | Q35818799 | ||
| TNF superfamily in inflammatory disease: translating basic insights | Q35821666 | ||
| Targeting CD40L: a promising therapeutic approach | Q35830859 | ||
| The two-signal model of lymphocyte activation twenty-one years later | Q35873663 | ||
| Small molecules, big targets: drug discovery faces the protein-protein interaction challenge | Q35981250 | ||
| Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. | Q35986113 | ||
| Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response | Q36368953 | ||
| OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation | Q36371325 | ||
| Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis | Q36375723 | ||
| An APRIL to remember: novel TNF ligands as therapeutic targets | Q36394955 | ||
| Between a rock and a hard place? | Q36399414 | ||
| Identification of proteoglycans as the APRIL-specific binding partners. | Q36403611 | ||
| iPPI-DB: an online database of modulators of protein-protein interactions. | Q36435078 | ||
| A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression | Q36447586 | ||
| Targeting protein-protein interactions by rational design: mimicry of protein surfaces | Q36539868 | ||
| Regulation of interleukin 2 gene expression by CD28 costimulation in mouse T-cell clones: both nuclear and cytoplasmic RNAs are regulated with complex kinetics | Q36551451 | ||
| Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. | Q36577841 | ||
| Binding efficiency of protein-protein complexes | Q36595042 | ||
| Protein-protein interactions as targets for small molecule drug discovery | Q36607010 | ||
| T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation | Q36614034 | ||
| Agonistic CD40 antibodies and cancer therapy | Q36664195 | ||
| Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival | Q36696891 | ||
| Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome | Q28280041 | ||
| Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28 | Q28288428 | ||
| Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding | Q28293146 | ||
| T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras | Q28300793 | ||
| How to improve R&D productivity: the pharmaceutical industry's grand challenge | Q28314992 | ||
| Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods | Q28473098 | ||
| Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database | Q28473129 | ||
| Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway | Q28488150 | ||
| Allosteric inhibition of the regulator of G protein signaling-Galpha protein-protein interaction by CCG-4986 | Q28568686 | ||
| Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts | Q28573846 | ||
| B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells | Q28590517 | ||
| Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis | Q28610610 | ||
| Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) | Q28822250 | ||
| Structure-based prediction of protein–protein interactions on a genome-wide scale | Q29012686 | ||
| Reaching for high-hanging fruit in drug discovery at protein-protein interfaces | Q29547258 | ||
| The druggable genome | Q29547361 | ||
| Anatomy of hot spots in protein interfaces | Q29616238 | ||
| Signalling pathways of the TNF superfamily: a double-edged sword | Q29616428 | ||
| A draft map of the human proteome | Q29617250 | ||
| Ligand efficiency: a useful metric for lead selection | Q29617403 | ||
| Small-molecule inhibitors of protein-protein interactions: progressing towards the dream | Q29617758 | ||
| KFC Server: interactive forecasting of protein interaction hot spots. | Q30369833 | ||
| Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. | Q30849102 | ||
| Privileged molecules for protein binding identified from NMR-based screening | Q30920894 | ||
| Rationalizing the chemical space of protein-protein interaction inhibitors | Q30962611 | ||
| Differential targeting of Gbetagamma-subunit signaling with small molecules | Q33240532 | ||
| Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds | Q33251011 | ||
| Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? | Q33337530 | ||
| Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154. | Q33382748 | ||
| A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors | Q33415880 | ||
| Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective | Q33536938 | ||
| Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial | Q33557015 | ||
| VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry | Q33688370 | ||
| The role of B7 costimulation in T-cell immunity. | Q33717482 | ||
| Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. | Q33729577 | ||
| A three-parameter two-state model of receptor function that incorporates affinity, efficacy, and signal amplification | Q33777942 | ||
| The promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia). | Q36745762 | ||
| Clinical targeting of the TNF and TNFR superfamilies | Q36762882 | ||
| The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. | Q36768345 | ||
| Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells | Q36769514 | ||
| B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling | Q36791432 | ||
| Scaffolds for blocking protein-protein interactions | Q36824992 | ||
| PD-1 and PD-1 ligands: from discovery to clinical application | Q36868261 | ||
| Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax | Q36958543 | ||
| In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice | Q36982753 | ||
| Costimulation blockade: towards clinical application | Q36992379 | ||
| TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties | Q37178196 | ||
| Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry | Q37185127 | ||
| Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. | Q37272524 | ||
| A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma | Q37325331 | ||
| Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial | Q37326017 | ||
| The role of TNF superfamily members in T-cell function and diseases | Q37332068 | ||
| Predicting druggable binding sites at the protein-protein interface. | Q37337290 | ||
| Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation | Q37342574 | ||
| Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus | Q37353822 | ||
| CD40 and autoimmunity: the dark side of a great activator. | Q37365433 | ||
| Two pathways of costimulation through CD28. | Q37392111 | ||
| Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation. | Q37412470 | ||
| Metabolism of azo dyes: implication for detoxication and activation | Q37437836 | ||
| Molecular mechanism and function of CD40/CD40L engagement in the immune system. | Q37474929 | ||
| Costimulatory pathways in transplantation: challenges and new developments. | Q37474958 | ||
| Endogenous programmed death ligand-1 restrains the development and onset of Sjӧgren's syndrome in non-obese diabetic mice | Q37501812 | ||
| Induction and maintenance of anergy in mature T cells | Q37512155 | ||
| Cracking the BAFF code. | Q37517172 | ||
| Targeting of BAFF and APRIL for autoimmunity and oncology | Q37598565 | ||
| Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance | Q37599837 | ||
| Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. | Q37641045 | ||
| The CD40-CD40L system in cardiovascular disease. | Q37829738 | ||
| BAFF inhibition: a new class of drugs for the treatment of autoimmunity | Q37844764 | ||
| Compliance in asthma | Q33798272 | ||
| Control of immunity by the TNFR-related molecule OX40 (CD134) | Q33899607 | ||
| Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes | Q34020310 | ||
| Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure | Q34077136 | ||
| Mechanisms of costimulation | Q34085850 | ||
| The molecular architecture of the TNF superfamily | Q34109796 | ||
| Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure | Q34115282 | ||
| Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity | Q34123595 | ||
| Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins | Q34128004 | ||
| Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? | Q34151594 | ||
| The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias | Q34171407 | ||
| Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn | Q34212755 | ||
| FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. | Q51026715 | ||
| Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. | Q51035537 | ||
| Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy. | Q51173694 | ||
| Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation | Q40566781 | ||
| The properties of known drugs. 1. Molecular frameworks | Q40933327 | ||
| Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation | Q40957673 | ||
| Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. | Q40982867 | ||
| Immune regulation by CD40 and its ligand GP39. | Q41039754 | ||
| Regulatory role of CD40 in obesity-induced insulin resistance | Q41179559 | ||
| Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). | Q41236133 | ||
| Recombinant soluble trimeric CD40 ligand is biologically active | Q41357988 | ||
| First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus | Q41417103 | ||
| Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Proteins | Q41470342 | ||
| Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to Diabetogenesis | Q41526144 | ||
| The crystal structure of the costimulatory OX40-OX40L complex | Q41791629 | ||
| Immunoglobulin fold characteristics of B7-1 (CD80) and B7-2 (CD86). | Q41837704 | ||
| Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. | Q41934667 | ||
| Immunomodulation of human intestinal T cells by the synthetic CD80 antagonist RhuDex® | Q42003625 | ||
| Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule | Q42162451 | ||
| Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. | Q42700822 | ||
| Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology | Q42701435 | ||
| The role of polar interactions in the molecular recognition of CD40L with its receptor CD40 | Q42846482 | ||
| BAFF mediates survival of peripheral immature B lymphocytes | Q42944182 | ||
| Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction | Q43286013 | ||
| Lessons from 60 years of pharmaceutical innovation | Q43447062 | ||
| A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects | Q43675694 | ||
| What do medicinal chemists actually make? A 50-year retrospective | Q43862892 | ||
| A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. | Q43961548 | ||
| Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases | Q44560131 | ||
| Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates | Q44765909 | ||
| Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions | Q44910586 | ||
| A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). | Q45837974 | ||
| Patient preferences and willingness to pay for different options of anticoagulant therapy | Q45881407 | ||
| Organic dyes as small molecule protein-protein interaction inhibitors for the CD40-CD154 costimulatory interaction. | Q45924236 | ||
| Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. | Q45965224 | ||
| Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects | Q46089805 | ||
| Structural diversity of organic chemistry. A scaffold analysis of the CAS Registry. | Q46164281 | ||
| Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo | Q46278994 | ||
| B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse | Q46346021 | ||
| CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes | Q46360981 | ||
| Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model | Q46893749 | ||
| Platelet pro-aggregatory effects of CD40L monoclonal antibody | Q46933293 | ||
| The role of molecular size in ligand efficiency | Q47286248 | ||
| Identification of protein-protein interfaces implicated in CD80-CD28 costimulatory signaling | Q47578963 | ||
| Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy. | Q47621604 | ||
| Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction | Q47661976 | ||
| The chemist as astronaut: searching for biologically useful space in the chemical universe | Q47691352 | ||
| Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. | Q47842052 | ||
| Structural and functional analysis of the costimulatory receptor programmed death-1. | Q47926421 | ||
| Stabilization of protein-protein interactions in drug discovery | Q47938743 | ||
| A subcellular map of the human proteome | Q48155823 | ||
| Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. | Q48278713 | ||
| Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. | Q48286199 | ||
| The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. | Q48339815 | ||
| Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? | Q49601705 | ||
| Autoimmune diseases surface after cancer treatment | Q49952129 | ||
| The food colorant erythrosine is a promiscuous protein-protein interaction inhibitor. | Q50549086 | ||
| Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. | Q50885033 | ||
| Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. | Q50948280 | ||
| Can emerging drug classes improve R&D productivity? | Q50966366 | ||
| P433 | issue | 8 | |
| P921 | main subject | protein-protein interaction | Q896177 |
| P304 | page(s) | 674-699 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Current Topics in Medicinal Chemistry | Q2734725 |
| P1476 | title | Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions | |
| P478 | volume | 18 |
| Q64938892 | A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data. |
| Q90007155 | CD40-targeting KGYY15 peptides do not efficiently block the CD40-CD40L interaction |
| Q88643533 | Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40⁻CD154 Costimulatory Protein-Protein Interaction |
| Q90171697 | HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes |
| Q98895957 | Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors |
| Q91523108 | Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells |
Search more.